We welcome the announcement from @GregHuntMP & Gilead Sciences that CAR T Cell Therapy Yescarta is now funded & available to eligible lymphoma patients. Sites at Royal Brisbane and Women’s Hospital, Brisbane @MetroNorthHHS & Peter Mac Cancer Centre, Melbourne. lymphoma.org.au/media/new-cart…

#POLARIX is Positive. RCHP-Pola versus RCHOP comes out in favour for the experimental arm. Well blow me down. Can’t wait to see the details. #lymsm roche.com/media/releases…

Pleased to be presenting the bispecific #glofitamab pivotal data for R/R Large B cell #lymphoma #DLBCL at #ASCO22 This press release contains updates on the abstract: bit.ly/38mxEgA #lymsm

Delighted that #glofitamab pivotal data for DLBCL is now online NEJM. 39.4% CR in patients with the most common aggressive #lymphoma, Fixed course, durable remissions, good safety profile, I hope this data changes practice for patients with R/R #DLBCL #ASH22 #lymsm Martin Hutchings

Congratulations to my mentor and colleague Michael Dickinson on the NEJM publication of the pivotal phase II glofitamab data in DLBCL. So grateful to be involved in ongoing IITs using this highly active agent! Martin Hutchings

Just out in The Lancet Haematology! Adrian Minson & I articulate the Haematology Peter MacCallum CC & Royal Melbourne approach to TP53-mutated MCL. From the limited data, we propose a rational approach to this high-risk clinical entity, where SoC Rx near universally fails. authors.elsevier.com/a/1gW5d8MsWYC5…

We have TWO great clinical/research #fellowships in #lymphoma starting Haematology Peter MacCallum CC & Royal Melbourne in 2024 (one focussing on indolent lymphoma, one on aggressive lymphoma) Job adverts now at bit.ly/3nDyVXT Please contact me if interested.

#pembrolizumab is deliverable and effective as a monotherapy first treatment of #hodgkin #lymphoma in very frail patients. Pleased to present #EHA2023 European Hematology Association and more detail to follow International Conference on Malignant Lymphoma Thanks to sites for years of effort! Judith Trotman #lymsm Peter Mac Cancer Centre

#Glofitamab now US FDA approved for #DLBCL after 2 prior lines! Highly potent (CR43%),FIXED course, durable responses. This is great for patients let's hope ROW follows! Proud to have contributed to the data underpinning this . #lymsm #ICML17 #ICMLugano bit.ly/3qS8C1F

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care & outcomes in a series from Australia & the UK onlinelibrary.wiley.com/doi/10.1111/bj… Adrian Minson @Mike_Dickinson1 @NadaHamad @prp_diciaccio @DrElizaHawkes Chan Cheah #lymsm

COALITION is online Journal of Clinical Oncology - an IIT and the FIRST bispecific #glofitamab First Line trial to target very high risk #DLBCL #lymphoma in younger pts. Great work from Adrian Minson and thanks to investigators and teams across Oz. #18ICML #lymsm and thanks to Peter Mac Cancer Centre

The GOlDiLOX trial is investigating the combination of pirtobrutinib + glofitamab in #MantleCellLymphoma that progresses after covalent BTKis.🩸 Want to learn more? Watch our interview w/ Michael Dickinson (Haematology Peter MacCallum CC & Royal Melbourne) from #EHA2025: 🎥 ow.ly/ifk450Wcf63 #LYMsm #CTSM

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study brnw.ch/21wTQuW Authored by Adrian Minson, Michael Dickinson, et al. #lymsm